Objective: In this retrospective cohort study, we assessed healthcare resource utilisation (HCRU) outcomes in People with Parkinson’s (PwP) naïve to Catechol-O-methyl transferase (COMT) inhibition via UK electronic healthcare records (Clinical Practice Research Datalink and Hospital Episodes Statistics databases, June 2016 to December 2019).

Background: The appearance of motor fluctuations (MF) is a crucial milestone in PwP as they are associated with increased disability and considerable HCRU. Management of MF may require add-on of enzymatic inhibitors such as COMT inhibitors. To date there has been a lack of head-to-head data comparing opicapone and entacapone, the two most commonly used COMT inhibitors in real-world settings.

Method: HCRU outcomes were assessed before (baseline) and after COMT inhibition at 0-6 months, 7-12 months, and 13-18 months. Opicapone treated PwP (n=173) were 1:4 algorithm-matched to entacapone-treated PwP (n=433).

Results: A significantly higher percentage of PwP in the entacapone-treated group had ≥1 neurology outpatient visits at 6-month follow-up compared to the opicapone-treated group (63% vs 44%, respectively, p <0.001). Head-to-head regression analyses (including age, sex, disease duration, baseline HCRU, and baseline medications as covariates) showed that PwP who received opicapone as their first line COMT inhibitor had 18.5% fewer neurology outpatient visits within 6 months of initiation compared to the entacapone-treated group.

Conclusion: This head-to-head study is the first to demonstrate using ‘real-world’ data that initiating COMT inhibition with opicapone is likely to decrease the need for post-treatment HCRU versus initiation of COMT inhibition with entacapone.

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/opicapone-versus-entacapone-head-to-head-comparison-of-healthcare-resource-utilisation-in-comt-i-naive-people-with-parkinsons/